Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Liabilities (2019 - 2021)

Nurix Therapeutics (NRIX) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $796000.0 as the latest value for Q3 2021.

  • Quarterly Other Non-Current Liabilities fell 8.29% to $796000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $796000.0 through Aug 2021, down 8.29% year-over-year, with the annual reading at $850000.0 for FY2020, 51.07% down from the prior year.
  • Other Non-Current Liabilities for Q3 2021 was $796000.0 at Nurix Therapeutics, down from $837000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $1.7 million in Q4 2019, with the low at $796000.0 in Q3 2021.
  • Average Other Non-Current Liabilities over 3 years is $986666.7, with a median of $843500.0 recorded in 2020.
  • The sharpest move saw Other Non-Current Liabilities plummeted 51.07% in 2020, then fell 8.29% in 2021.
  • Over 3 years, Other Non-Current Liabilities stood at $1.7 million in 2019, then tumbled by 51.07% to $850000.0 in 2020, then fell by 6.35% to $796000.0 in 2021.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $796000.0, $837000.0, and $832000.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.